Proteomic Stratification Test Can Help Guide Second-Line Treatment of NSCLC
A simple serum protein test can help guide treatment decisions between chemotherapy and erlotinib as second-line therapy for patients with non-small-cell lung cancer, according to results of a phase III study presented at ASCO. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news
Ovarian Cancer: Erlotinib Biological Maintenanc...
Ovarian cancer is initially treated with surgery and chemotherapy. But is this enough? Learn about research regarding maintenance therapy with erlotinib or Tarceva, a biological agent. (Source: About.com Ovarian Cancer)
Source: About.com Ovarian Cancer - June 5, 2013 Category: Cancer & Oncology Tags: health Source Type: news
EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
(European Organisation for Research and Treatment of Cancer) EORTC trial 40084-22084 has two primary objectives: To determine if adding erlotinib to gemcitabine adjuvant chemotherapy will improve survival as compared to gemcitabine alone following resection of head of pancreas adenocarcinoma, then, following adjuvant chemotherapy, to determine if concurrent fluoropyrimidine and radiotherapy improves survival for patients who have no evidence of progressive disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2013 Category: Global & Universal Source Type: news
FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
The FDA approved a label expansion for erlotinib (Tarceva), along with the cobas EGFR mutation diagnostic test, to include patients untreated metastatic NSCLC patients whose tumors have either a deletion in exon 19 or exon 21 (L858R) substitution mutations in the EGFR gene. (Source: Cancer Network)
Source: Cancer Network - May 16, 2013 Category: Cancer & Oncology Source Type: news
FDA approves Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer
Tarceva is the first personalised medicine approved for the initial treatment of people with EGFR mutation-positive advanced non-small cell lung cancer in the United States. (Source: Roche Media News)
Source: Roche Media News - May 15, 2013 Category: Pharmaceuticals Source Type: news
FDA approves Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer
Tarceva is the first personalised medicine approved for the initial treatment of people with EGFR mutation-positive advanced non-small cell lung cancer in the United States. Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Tarceva (erlotinib) tablets for the initial (first-line) treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have certain epidermal growth factor receptor (EGFR) activating mutations as detected by a FDA approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - May 15, 2013 Category: Pharmaceuticals Source Type: news
FDA Approves New Lung Cancer Diagnostic "Cobas EGFR Mutation Test"
The U.S. Food and Drug Administration (FDA) has approved the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10 percent of non-small cell lung cancers (NSCLC). Patients with such genetic mutations generally benefit from treatment with an anti-EGFR tyrosine kinase inhibitor, such as Roche's Tarceva (erlotinib)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 15, 2013 Category: Consumer Health News Tags: Lung Cancer Source Type: news
FDA OKs Test for Use with Tarceva
WASHINGTON (MedPage Today) -- The FDA has approved a companion EGFR mutation test for use with the targeted cancer drug erlotinib (Tarceva) to help guide decision making in non-small cell lung cancer. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 15, 2013 Category: Hematology Source Type: news
FDA approves Tarceva for first-line treatment in patients with NSCLC
(Source: HemOncToday.com)
Source: HemOncToday.com - May 15, 2013 Category: Cancer & Oncology Source Type: news
FDA Approves Companion Genetic Diagnostic Test for TarcevaFDA Approves Companion Genetic Diagnostic Test for Tarceva
The FDA has approved the first companion diagnostic test that can detect EGFR mutations in non-small cell lung cancer. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 14, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA approves Roche diagnostic for gene mutation in lung cancer
(Reuters) - U.S. health regulators on Tuesday approved a test developed by Roche for a specific gene mutation present in about 10 percent of non-small cell lung cancers, and said the company's drug Tarceva could be used as an initial treatment in patients with the mutation whose cancer has spread beyond the lungs. (Source: Reuters: Health)
Source: Reuters: Health - May 14, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves first companion diagnostic to detect gene mutation associated with a type of lung cancer
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10 percent of non-small cell lung cancers (NSCLC). (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 14, 2013 Category: American Health Source Type: news
Addition of erlotinib to cisplatin did not increase response PFS in SCCHN
Martins RG. J Clin Oncol. 2013;doi:10.1200/JCO.2012.46.3299. (Source: HemOncToday.com)
Source: HemOncToday.com - April 26, 2013 Category: Cancer & Oncology Source Type: news
Erlotinib may improve life quality in advanced NSCLC
Treating advanced epidermal growth factor receptor-mutation-positive non-small-cell lung cancer with erlotinib appears to improve quality of life compared with standard first-line chemotherapy, study results indicate. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - April 2, 2013 Category: Cancer & Oncology Source Type: news
